07:32 EDT Viridian Therapeutics (VRDN) files automatic mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics: Strong Clinical Progress and Strategic Developments Justify Buy Rating
- Viridian Therapeutics price target raised to $32 from $28 at Oppenheimer
- Optimistic Outlook for Viridian Therapeutics: Strategic Advances and Market Potential in TED Treatment
- Viridian Therapeutics price target lowered to $26 from $27 at Wells Fargo
- Viridian Therapeutics: Hold Rating Amidst Stable Near-Term Outlook and Awaited 2026 Developments